New Drug Product: Kesimpta
This slideshow shows drug information for Kesimpta. Click here for the complete Kesimpta monograph.
Multiple Sclerosis
Bafiertam Now Available for Relapsing Forms of Multiple Sclerosis
Bafiertam is a novel fumarate bioequivalent alternative to its prodrug dimethyl fumarate.
Kesimpta Approved for Relapsing Forms of Multiple Sclerosis
Kesimpta, a CD20-directed cytolytic monoclonal antibody, is the first B-cell therapy intended for patient self-administration.
Mylan Launches Generic Version of Tecfidera for MS
This is the first FDA-approved therapeutically equivalent, substitutable generic of Tecfidera.
Complementary, Alternative Medicine Use Increasing for MS
Ninefold increase observed in likelihood of patients speaking to their neurologist about CAM use.
Therapeutic Hookworm Explored for Relapsing Multiple Sclerosis
No effect seen for hookworm vs placebo on number of new/enlarging/enhancing lesions.
New Oral Treatment for Relapsing Forms of MS Now Available
Zeposia® (ozanimod; Bristol Myers Squibb) is now available for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Rebif Labeling Updated with Pregnancy, Lactation Data
The FDA has approved updated labeling for Rebif® (has approved updated labeling for Rebif® (interferon beta-1a; EMD Serono) to include the addition of new safety data on pregnancy and lactation.interferon beta-1a; EMD Serono) to include the addition of new safety data on pregnancy and lactation.
Ofatumumab Bests Teriflunomide in Halting Disease Activity in MS Patients
Treatment with ofatumumab (Novartis) was associated with a greater proportion of patients with relapsing forms of multiple sclerosis (RMS) achieving no evidence of disease activity (NEDA-3), compared with those who received teriflunomide, according to post hoc analysis of the phase 3 ASCLEPIOS trials.
Bafiertam Gets Final FDA Approval for Multiple Sclerosis
The FDA has granted final approval to Bafiertam™ (monomethyl fumarate; Banner Life Sciences) for the treatment of relapsing forms of multiple sclerosis.
